Yeung SMH, Binnenmars SH, Gant CM, et al. - In patients with T2D and normal or mildly impaired kidney function, researchers ascertained if fibroblast growth factor 23 (FGF23) was correlated with adverse outcomes. In 310 individuals with T2D and estimated glomerular filtration rate ≥ 60 mL/min/1.73 m², COOH-terminal FGF23 levels were analyzed. Forty-seven patients developed major adverse cardiovascular events and 28 patients died during a follow-up of 5.8 years (3.3–6.5). FGF23 is linked to an increased risk of cardiovascular events and mortality in patients with T2D and normal or mildly impaired kidney function.